[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
August 1957

The Exocrine Function of the Pancreas in Psoriasis

Author Affiliations

San Francisco; Boston

From the Division of Dermatology, Stanford University Hospitals (Dr. Farber). Fellow in Dermatology, Stanford University School of Medicine (Dr. Johnsen). Assistant Professor of Pediatrics, Harvard Medical School; Chief, Division of Clinical Laboratories, and Physician, Children's Medical Center (Dr. Shwachman).

AMA Arch Derm. 1957;76(2):236-238. doi:10.1001/archderm.1957.01550200080016


During the past quarter century, a number of reports have suggested that psoriasis is induced or aggravated by altered exocrine pancreatic function. The present study is intended to clarify the exocrine role of the pancreas in psoriasis.

Ingels1 in 1953 claimed good clinical results in the majority of 36 psoriasis patients who received pancreatic enzyme replacement therapy. Earlier favorable clinical reports of Dragstedt, Becker, Stewart, Clark, and Walsh2-4 using alcoholic pancreatic extract, "lipocaic," are well known. Clinical improvement with a variety of pancreatic preparations has been reported by other investigators.5-7 At present, there are a number of commercial preparations available whose primary constituents are pancreatic enzymes, which have been said to be of value in psoriasis.

Madden and Karon8 found no significant variation in pancreatic exocrine function in psoriasis. They employed only indirect measurement through study of fecal nitrogen, fecal fat,